Core Insights - Brothers Technology is the largest global supplier of Vitamin K3, established in March 2001 and listed on the Shenzhen Stock Exchange in March 2011 [1] Group 1: Business Performance - For Q3 2025, Brothers Technology reported revenue of 2.725 billion yuan, ranking 7th in the industry, below the top competitors Meihua Biological (18.215 billion yuan) and New Hope Liuhe (16.642 billion yuan) [2] - The company's net profit for the same period was 101 million yuan, ranking 14th in the industry, significantly lower than New Hope Liuhe (5.354 billion yuan) and Meihua Biological (3.025 billion yuan) [2] Group 2: Financial Ratios - As of Q3 2025, Brothers Technology's debt-to-asset ratio was 42.72%, higher than the industry average of 28.46% [3] - The gross profit margin for the same period was 18.42%, which is an increase from 15.54% year-on-year but still below the industry average of 28.77% [3] Group 3: Executive Compensation - Chairman Qian Zhida's salary for 2024 was 1.5621 million yuan, an increase of 205,300 yuan from 2023 [4] - General Manager Li Jianping's salary for 2024 was 1.0143 million yuan, up by 171,600 yuan from the previous year [4] Group 4: Shareholder Information - As of June 30, 2025, the number of A-share shareholders increased by 19.32% to 62,900 [5] - The average number of circulating A-shares held per shareholder decreased by 16.19% to 11,200 [5]